GERN

Geron Corporation

GERN.US geron.com + Research + Basket
CIK 0000886744
Employees 258
Phone 650 473 7700
Fiscal year end December
IPO Jun 30, 1996
Address 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
1.08
+0.15 (+16.13%)
USD · NASDAQ
52-week range
0.84
2.01
Trading at 21% of the 52-week range
Market Cap
597.50M
P/E Ratio
0.00
Forward P/E
46.51
Book Value
0.34
Div. Yield
N/A
% Institutions
77.07%
% Insiders
0.081%

1 Year

-6.1%

3 Year

-41.6%

10 Year

-43.8%
Description

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Actions

Add an action for GERN.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Harout Semerjian CEO, President & Director 1970
Ms. Michelle J. Robertson EVP, CFO, Treasurer and Principal Financial & Accounting Officer 1967
Dr. Joseph Emile Eid M.D. Executive VP of Research & Development and Chief Medical Officer 1967
Mr. Ahmed ElNawawi Executive VP & Chief Commercial Officer 1981
Mr. Shanthakumar Tyavanagimatt Senior VP & Chief Technical Officer NA
Ms. Dawn Schottlandt CFA Senior Vice President of Investor Relations & Corporate Affairs NA
Mr. Timothy Williams J.D. Executive VP, Chief Legal Officer & Corporate Secretary 1977
Ms. Aron Feingold Vice President of Investor Relations & Corporate Communications NA
Ms. Shannon T. Odam Executive VP & Chief People Officer 1975
Mr. Bryan Ridgell Senior VP of Portfolio & Project Management and Chief of Staff NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Feb 27, 2025 John A Scarlett N/A Purchase 12.50K $1.76 $22.00K SEC
Feb 27, 2025 Scott Alan Samuels N/A Purchase 15.00K $1.61 $24.15K SEC
Jul 08, 2024 Andrew J. Grethlein N/A Sale 674.35K $4.56 $3.08M SEC
Jun 10, 2024 Faye Feller N/A Sale 287.90K $4.63 $1.33M SEC
Jun 04, 2024 John A Scarlett N/A Sale 600.00K $4.00 $2.40M SEC
Aug 24, 2023 Elizabeth G O'farrell N/A Purchase 6.61K $2.28 $15.06K SEC
May 11, 2023 V Bryan Lawlis N/A Sale 35.00K $3.00 $105.00K SEC
May 01, 2023 Susan Molineaux N/A Sale 35.00K $2.48 $86.80K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 49.12M Jun 30, 2026 7.64% $0.00 3.80%
RA Capital Management, LLC 42.81M Jun 30, 2026 6.66% $0.48 -32.87%
Soleus Capital Management, L.P. 42.81M Jun 30, 2026 6.66% $1.89 3.13%
State Street Corp 35.86M Jun 30, 2026 5.58% $0.00 17.57%
Citadel Advisors Llc 29.04M Jun 30, 2026 4.52% $0.00 34.59%
Vanguard Capital Management, LLC 27.25M Jun 30, 2026 4.24% $0.00 2.18%
Nantahala Capital Management, LLC 24.45M Jun 30, 2026 3.81% $0.52 117.82%
ClearBridge Advisors, LLC 19.65M Jun 30, 2026 3.06% $0.02 0.15%
Eversept Partners, LP 18.72M Jun 30, 2026 2.91% $1.24 -0.62%
The Goldman Sachs Group Inc 16.63M Jun 30, 2026 2.59% $0.00 48.82%
Geode Capital Management, LLC 14.56M Jun 30, 2026 2.27% $0.00 6.47%
Morgan Stanley - Brokerage Accounts 12.95M Jun 30, 2026 2.01% $0.00 2.21%
Vanguard Portfolio Management, LLC 10.81M Jun 30, 2026 1.68% $0.00 131.59%
Vivo Capital, LLC 8.67M Jun 30, 2026 1.35% $1.01 0.00%
Millennium Management LLC 8.11M Jun 30, 2026 1.26% $0.00 10.80%
Kynam Capital Management, LP 6.84M Jun 30, 2026 1.06% $0.48 0.00%
Candriam Luxembourg S.C.A. 5.59M Jun 30, 2026 0.87% $0.03 42.53%
FMR Inc 5.50M Jun 30, 2026 0.86% $0.00 -16.59%
Pale Fire Capital SE 5.31M Jun 30, 2026 0.83% $0.48 8.57%
Northern Trust Corp 5.03M Jun 30, 2026 0.78% $0.00 3.50%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 20.45M 3.18% ▲ 0.00% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 18.87M 2.94% ▼ 0.80% Oct 29, 2026
3 iShares Russell 2000 ETF 13.97M 2.17% ▼ 0.41% Oct 29, 2026
4 Vanguard Explorer Inv 12.98M 2.02% ▲ 0.00% Sep 30, 2026
5 ClearBridge Small Cap Growth A 6.32M 0.98% ▲ 0.00% Sep 30, 2026
6 Fidelity Small Cap Index 6.10M 0.95% ▲ 0.36% Jul 31, 2026
7 Belfius Equities Cure C Cap 5.59M 0.87% ▲ 42.53% Apr 30, 2026
8 Fidelity Select Biotechnology 5.45M 0.85% ▲ 0.00% Aug 31, 2026
9 iShares Russell 2000 Growth ETF 5.32M 0.83% ▲ 0.25% Oct 29, 2026
10 iShares Biotechnology ETF 4.96M 0.77% ▼ 0.19% Oct 29, 2026

Financial Highlights

▼
Market Cap: $597.50M
EBITDA: $-34.80M
PEG Ratio: $-2.38
Book Value: $0.34
Earnings/Share: $-0.11
Profit Margin: -33.05%
Operating Margin: -22.01%
ROA (TTM): -4.11%
ROE (TTM): -28.28%
Revenue (TTM): $204.56M
Revenue/Share (TTM): $0.31
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 17.20%

Valuation Metrics

Enterprise Value: $418.22M
Trailing P/E: 0.00
Forward P/E: 46.51

Shares Statistics

Shares Outstanding: 642.47M
Shares Float: 556.31M
% Insiders: 0.081%
% Institutions: 77.07%
Shares Short: 74.61M
Shares Short (Prior Month): 73.89M
Short Ratio: 8.16
Short % Float: 11.62%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$183.88M
Cost of Goods Sold
adjust
$-4.75M
Gross Profit
subtotal
$179.14M
SG&A
adjust
$-159.26M
R&D
adjust
$-73.72M
Operating Income
subtotal
$-53.84M
Other / Non-Operating Items
adjust
$-31.95M
Net Income
subtotal
$-85.78M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GERN.US!